Bezpieczeństwo wspó czesnej terapii hormonalnej menopauzy opartej na niskich dawkach estradiolu i octanu noretisteronu

Results of the large clinical trials Women’s Health Initiative (WHI), the Heart and Estrogen/progestin ReplacementStudy (HERS), and the Million Women Study (MWS) changed doctors’ and patients’ view of hormonaltherapy and narrowed the indications for this treatment. Contemporary menopausal hormonal therapy, besidestherapeutic safety, has to be highly individualized – adjusted to a particular patient’s needs, “tailor-made” forher (tailored therapy), and ensure understanding and compliance with the treatment regimen.The main advantage of low dose hormonal therapy is a similar therapeutic effect to therapy based on higherdoses but with lower probability of adverse effects.To meet therapy safety and individualization requirements, one should remember about the correct choiceof progestin, regarding possible adverse effects of this compound